

APD926Hu01 100μg

Active Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14)

Organism Species: Homo sapiens (Human)

Instruction manual

FOR IN VITRO USE AND RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

1st Edition (Apr, 2016)

### [PROPERTIES]

Source: Prokaryotic expression.

Host: E. coli

Residues: Ser41~Ser209 Tags: N-terminal His-tag

**Purity: >95%** 

Buffer Formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl

and 5% trehalose.

**Applications:** Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 6.8

Predicted Molecular Mass: 21.6kDa

Accurate Molecular Mass: 22kDa as determined by SDS-PAGE reducing conditions.

### [USAGE]

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## [STORAGE AND STABILITY]

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.



**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

### [SEQUENCE]

SCKEDEYPVG

SECCPKCSPG YRVKEACGEL TGTVCEPCPP GTYIAHLNGL SKCLQCQMCD PAMGLRASRN CSRTENAVCG CSPGHFCIVQ DGDHCAACRA YATSSPGQRV QKGGTESQDT LCQNCPPGTF SPNGTLEECQ HQTKCSWLVT KAGAGTSSSH WVWWFLSGS

#### [ACTIVITY]

TNFRSF14 (Tumor necrosis factor receptor superfamily member 14) belongs to the tumor necrosis factor receptor superfamily. TNFRSF14 functions in signal transduction pathways that activate inflammatory and inhibitory T-cell immune response. It binds herpes simplex virus (HSV) viral envelope glycoprotein D (gD), mediating its entry into cells. A binding ELISA assay was conducted to detect the association of TNFRSF14 with TNFa. Briefly, TNFRSF14 were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100uL TNFRSF14 were then transferred to TNFa-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-TNFRSF14 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of TNFRSF14 and TNFa was shown in Figure 1, and this effect was in a dose dependent manner.




Figure 1. The binding activity of TNFRSF14 with TNFa.

# [ IDENTIFICATION ]




Figure 2. SDS-PAGE

Sample: Active recombinant TNFRSF14, Human




Figure 3. Western Blot

Sample: Recombinant TNFRSF14, Human;

Antibody: Rabbit Anti-Human TNFRSF14 Ab (PAD926Hu01)